Should we consider calcimimetics as a therapeutic option for nephrotic syndrome? - Archive ouverte HAL Access content directly
Journal Articles Kidney International Year : 2022

Should we consider calcimimetics as a therapeutic option for nephrotic syndrome?

(1, 2) , (1, 2)
1
2

Abstract

Calcimimetics allosterically increase the calcium ion sensitivity of the calcium-sensing receptor (CaSR). Using a CaSR knockdown in podocytes and a podocyte-specific CaSR knockout in mice, Mühlig et al. uncovered a stabilizing role for actin cytoskeleton and cell adhesion. Short-term alleviation of albuminuria and proteinuria was observed in 4 children treated with cinacalcet. Here we discuss the potential mechanisms whereby CaSR displays a favorable effect in podocytes and the context in which calcimimetics may alleviate nephrotic syndrome.
Loading...
Not file

Dates and versions

inserm-03788305 , version 1 (26-09-2022)

Identifiers

Cite

Olivia Lenoir, Pierre-Louis Tharaux. Should we consider calcimimetics as a therapeutic option for nephrotic syndrome?. Kidney International, 2022, 101 (6), pp.1110-1112. ⟨10.1016/j.kint.2022.04.008⟩. ⟨inserm-03788305⟩

Collections

INSERM UP-SANTE
1 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More